| Consequences of acute myelogenous leukemia in early pregnancy. | |
| | |
MedLine Citation:
|
PMID: 332324 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Cytarabine and thioguanine therapy for acute myelomonocytic leukemia initiated in the tenth week of pregnancy (with the addition of vincristine and rubidomycin at 17 weeks) led to a short complete remission of the leukemia in a 24-year-old primigravida. This is the first case to be reported in which cytarabine was administered in the first trimester and a prostaglandin termination of pregnancy performed at 20 weeks produced an apparently normal fetus. A review of the literature suggests a slightly less than 50% chance of producing a live healthy baby if acute myelogenous leukemia is diagnosed in the first half of pregnancy, with materna mortality approaching 100% by six months postpartum. Current therapy may improve these figures. |
| | |
Authors:
|
J S Lilleyman; A S Hill; K J Anderton |
Related Documents
:
|
23658134 - Long-term neurodevelopmental and cardiovascular outcome after intrauterine transfusions... 23644584 - Experimental methods for testing the effects of neurotrophic peptide, adnf-9, against a... 21772674 - Subarachnoid block for caesarean section in severe preeclampsia. 22113514 - Exercise, sports participation, and musculoskeletal disorders of pregnancy and postpartum. 12542144 - Evaluation of a fixed-time artificial insemination protocol for postpartum suckled beef... 23341654 - Motherisk update: reproductive outcomes after assisted conception. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Cancer Volume: 40 ISSN: 0008-543X ISO Abbreviation: Cancer Publication Date: 1977 Sep |
Date Detail:
|
Created Date: 1977-11-25 Completed Date: 1977-11-25 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0374236 Medline TA: Cancer Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 1300-3 Citation Subset: AIM; IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Abortion, Therapeutic Antineoplastic Agents / adverse effects, therapeutic use* Cytarabine / therapeutic use Daunorubicin / therapeutic use Drug Therapy, Combination Female Humans Infant Mortality Infant, Newborn Leukemia, Myeloid / drug therapy, mortality Leukemia, Myeloid, Acute / complications* Pregnancy Pregnancy Complications, Hematologic / drug therapy*, mortality Pregnancy Trimester, First Pregnancy Trimester, Second Risk Teratogens Thioguanine / therapeutic use Vincristine / therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Teratogens; 147-94-4/Cytarabine; 154-42-7/Thioguanine; 20830-81-3/Daunorubicin; 57-22-7/Vincristine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The epidemiology of bladder cancer: a second look.
Next Document: Characterization of urothelial carcinoma with respect to the content of carcinoembryonic antigen in ...